Efficacy and Safety Study of Neramexane to Treat Congenital and Acquired Nystagmus

Efficacy and Safety of Neramexane Mesylate in Congenital Idiopathic Nystagmus and Acquired Nystagmus: a Randomized, Double-blind, Placebo-controlled, Single Center, Proof of Concept Study Using a Two-period Cross-over Design

The purpose of this study is to investigate the safety and efficacy of neramexane mesylate in the treatment of congenital idiopathic nystagmus (CIN) in comparison to placebo. In addition, a subgroup of multiple sclerosis (MS) patients suffering from acquired nystagmus will be included; this subgroup will be analyzed in an exploratory manner only.

Inclusion Criteria:

• patients with congenital idiopathic nystagmus or acquired nystagmus subsequent to multiple sclerosis
• male or female outpatients
• aged between 18 and 80 years (inclusive) at screening

Exclusion Criteria:

• patients with evidence of neurologic disorders other than CIN such as congenital nystagmus due to albinism or retinal diseases and/or acquired nystagmus (exemption: secondary to MS)